Liu, Ling
Zhao, Chen
Li, Li
Guo, Liangdong
Che, Yongsheng
Pestalotriols A (1) and B (2), two new metabolites featuring a unique spiro[2.5]octane skeleton, were isolated from an endophytic fungus Pestalotiopsis fici. Their structures were elucidated primarily by NMR experiments, and the absolute configurations of 1 and 2 were assigned by electronic circular dichroism calculations.
Provided in the present invention is an embedded distributed networking method, comprising: a network topology formation step; an initial routing generating step; a real-time routing maintenance step; and a message transmission routing step. Also provided in the present invention is an embedded distributed networking system. The technical solution provided in the present invention uses the four steps to greatly improve the efficiency of electric meter reading.
A locking component (100) comprises a first member (1) and a second member (2) used to engage with the first member (1). The first member (1) comprises a locking seat (11) and a first connector (12) disposed in the locking seat (11). The second member (2) comprises a base (21), a second connector (22), a sliding seat (23), a handle (24), a driver (25), and a latch hook (26). The locking component (100) enables interlocking of the first and second members (1, 2) and insertion connection of the connectors (12, 22) at the same time, thus being time- and labor-efficient and easy to operate. Also provided is a modular LED screen. The modular LED screen has a simplified installation process and is more convenient and easy to use. LED cabinets (200) can be rapidly joined or separated, thereby improving the installation efficiency.
The present invention relates to the technical field of communications. Disclosed is a signal processing method. The method comprises: receiving an optical signal, converting the optical signal into an electrical signal, and converting the electrical signal into a digital signal; extracting, from the digital signal, a left sideband pilot and a right sideband pilot, calculating the power of the left sideband pilot and the power of the right sideband pilot, and obtaining phase detection information by performing calculation according to a power sum of the left sideband pilot and a power sum of the right sideband pilot; inserting the phase detection information into an optical signal to be transmitted, and transmitting the optical signal inserted with the phase detection information. In an embodiment of the present invention, the phase detection information is obtained, via insertion of a pilot and calculation of the power of the left sideband pilot and the power of the right sideband pilot with a power function, by performing calculation according to the power sum of the left sideband pilot and the power sum of the right sideband pilot. The obtained phase detection information can accurately reflect a frequency offset of a transmission signal from a second node, enabling the second node to accurately adjust the frequency of the transmission signal.
The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one resistin agonist, resistin polynucleotide and/or resistin polypeptide for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.
The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist, LP82 antagonist, LP82 polynucleotide, LP82 polypeptide, and/or LP82 antibody for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.
A new method of synthesizing hybrid organic and carbon xerogel using graphene oxide as the cross-linking agent in the polycondensation of phenol and formaldehyde is presented. The organic xerogel is dried under ambient conditions, and the graphene cross-linked phenol-formaldehyde hybrid carbon xerogel (GCPFCX) is obtained through carbonization. Mechanically strong graphene oxide (GO) increases gel skeleton strength, giving organic xerogel very low drying shrinkage, low density and high mechanical property. The GCPFCX exhibits a layered structure, indicating a change in the gel structure resulting from the addition of GO. The PF molecular chains possibly grow along the GO surface because of strong interactions between the two compounds.
Liu, Ling
Dong, Ying
Ye, Mei
Jin, Shi
Yang, Jianbo
Joosse, Maria E.
Sun, Yu
Zhang, Jennifer
Lazarev, Mark
Brant, Steven R.
Safar, Bashar
Marohn, Michael
Mezey, Esteban
Li, Xuhang
The present invention relates to at least one novel IL-17 homolog polypeptide, including isolated nucleic acids that encode at least one IL-17 homolog polypeptide, IL-17 homolog polypeptides, vectors, host cells, transgenics, chimerics, and methods of making and using thereof same, as well as IL-17-homolog-specific antibodies and methods.
We aimed to assess the prognostic role of liver function alteration with intravenous immunoglobulin (IVIG) resistance in patients with Kawasaki disease (KD) by systematically analyzing and summarizing the results from published studies. In this study, we summarized the evidence currently available up to March 31, 2015, and calculated the standard mean difference (SMD) of liver function parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total bilirubin between IVIG-responsive and IVIG-resistant patients. We found that the serum levels of these parameters in IVIG-non-responsive patients were significantly higher than that in IVIG-responsive group (total bilirubin: SMD = 0.984, 95 %CI 0.712–1.184, p < 0.005; ALT: SMD = 0.555, 95 %CI 0.400–0.710, p < 0.005; AST: SMD = 0.602, 95 %CI 0.413–0.791, p < 0.005; GGT = 0.551, 95 %CI 0.157–0.946, p = 0.006). There was evidence of heterogeneity (I 2 > 50 %). The characteristics of patients could be the major sources, as analysis stratified by region significantly removed or reduced the heterogeneity. In summary, our meta-analysis suggested that liver abnormality was significantly associated with IVIG unresponsiveness in KD patients. Further study from more clinical investigations is needed to confirm this finding.